SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor

Category: Promising drugs and vaccines and Treatment

Preprint: Preprint

Tags: ACE2, antiviral, laboratory trials, scheme, serine protease, TMPRSS2, treatment, and viral entry

Source: ScienceDirect

Source link:

Date of publication: 03/05/2020

Added: 03/06/2020 07:59

Download PDF